Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-10014.23%
operating margin TTM
-9465.46%
revenue TTM
488.72 Thousand
revenue per share TTM
0.03$
valuation ratios | |
|---|---|
| pe ratio | -10.72 |
| peg ratio | 0.10 |
| price to book ratio | -66.35 |
| price to sales ratio | 1,010.62 |
| enterprise value multiple | -12.55 |
| price fair value | -66.35 |
profitability ratios | |
|---|---|
| gross profit margin | -35.62% |
| operating profit margin | -9465.46% |
| pretax profit margin | -10014.08% |
| net profit margin | -10014.23% |
| return on assets | -70.77% |
| return on equity | -563.89% |
| return on capital employed | -78.15% |
liquidity ratios | |
|---|---|
| current ratio | 6.46 |
| quick ratio | 6.46 |
| cash ratio | 6.10 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 52.22 |
| days of payables outstanding | 1,814.03 |
| cash conversion cycle | -1,761.80 |
| receivables turnover | 6.99 |
| payables turnover | 0.20 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.03 |
| debt equity ratio | -0.28 |
| long term debt to capitalization | -0.20 |
| total debt to capitalization | -0.39 |
| interest coverage | -9.45 |
| cash flow to debt ratio | -22.35 |
cash flow ratios | |
|---|---|
| free cash flow per share | -8.47 |
| cash per share | 10.37 |
| operating cash flow per share | -8.46 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -22.35 |
| short term coverage ratios | -54.79 |
| capital expenditure coverage ratio | -13,192.50 |
Frequently Asked Questions
When was the last time Inhibrx Biosciences, Inc. (NASDAQ:INBX) reported earnings?
Inhibrx Biosciences, Inc. (INBX) published its most recent earnings results on 14-05-2026.
What is Inhibrx Biosciences, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Inhibrx Biosciences, Inc. (NASDAQ:INBX)'s trailing twelve months ROE is -563.89%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Inhibrx Biosciences, Inc. (INBX) currently has a ROA of -70.77%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did INBX's net profit margin stand at?
INBX reported a profit margin of -10014.23% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is INBX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.46 in the most recent quarter. The quick ratio stood at 6.46, with a Debt/Eq ratio of -0.28.